ABBV-903
Sponsors
AbbVie
Conditions
Healthy VolunteerHealthy Volunteers
Phase 1
A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults
CompletedNCT05691699
Start: 2023-01-03End: 2023-10-23Updated: 2023-10-30
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
CompletedNCT05895266
Start: 2023-06-23End: 2023-11-02Updated: 2023-11-09
A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration
CompletedNCT05995366
Start: 2023-08-18End: 2023-10-13Updated: 2023-10-26
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants
TerminatedNCT06009237
Start: 2023-08-23End: 2023-10-30Updated: 2023-11-13
A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult Volunteers
WithdrawnNCT06078202
Start: 2024-12-01End: 2025-01-31Updated: 2024-09-20